U.S. Markets closed

Analysts See a Strong Upside in Novavax Stock

Kenneth Smith
Analysts See a Strong Upside in Novavax Stock

In September 2018, of the total eight analysts covering Novavax (NVAX), five analysts have given Novavax stock a “buy” or higher rating, and three analysts have given Novavax a “hold” rating. The mean rating for Novavax stock is 2.13 with a target price of $3.86, implying an upside potential of 141.3% over Novavax’s closing price of $1.60 as of September 21.